Orforglipron Dosing: 0.8mg Oral Titration

The approved label for orforglipron (Foundayo) describes starting at 0.8 mg once daily and increasing at intervals of at least roughly 30 days to a maximum of 17.2 mg once daily. The Phase 3 obesity and diabetes trials instead used fixed 6, 12, and 36 mg once-daily doses, titrated up from a low starting dose over several weeks. It is an oral tablet taken once a day, at any time, with no food or water restriction.

Research-context information only. Orforglipron is the active ingredient in an FDA-approved prescription product (Foundayo) for chronic weight management; it is available only by prescription and is not sold as a research chemical. The doses, titration schedules, and adverse events reported below come from published clinical trials and the approved product labeling. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Orforglipron is a once-daily, non-peptide oral GLP-1 receptor agonist — a small molecule rather than an injectable peptide, so there is no reconstitution, no bacteriostatic water, and no syringe math. This guide reports the label's titration schedule, the fixed doses the pivotal trials used, why the dose is stepped up gradually, and how weight loss and A1c tracked with each dose level.

Quick Reference: Label and Trial Dosing

The table below reports two separate things: the schedule the approved Foundayo label describes, and the fixed doses the pivotal clinical trials administered. They are not the same — the commercial label titrates through low tablet strengths, while the trials used 6, 12, and 36 mg capsules.

Intermediate commercial tablet strengths between the 0.8 mg start and the 17.2 mg maximum have been reported, but the exact strength list should be verified against the current FDA label before it is relied on. A direct milligram equivalence between the 36 mg trial capsule and the 17.2 mg maximum tablet has not been established and should not be assumed — the trial and commercial products used different formulations.

Titration Schedule

Two distinct titration approaches appear in the record.

Approved label (Foundayo). The label describes initiating at 0.8 mg once daily and increasing the dose at intervals of at least about 30 days, up to the 17.2 mg once-daily maximum. Monthly steps give the gastrointestinal system time to adapt before each increase.

Clinical trials. The pivotal trials did not titrate through the commercial tablet strengths. In the ACHIEVE-1 type 2 diabetes trial, dosing began at 1 mg once daily and stepped up every 4 weeks toward the assigned target of 3, 12, or 36 mg (Rosenstock et al., 2025). The obesity trials likewise escalated from a low starting dose to fixed 6, 12, or 36 mg maintenance doses over several weeks.

Why Titration Matters

Orforglipron's adverse events are dominated by gastrointestinal effects that rise with dose, which is the reason both the label and the trials increase the dose gradually rather than starting at target.

In ATTAIN-1, the 36 mg group reported nausea in 33.7% versus 10.4% on placebo, vomiting in 24.0% versus 3.5%, diarrhea in 23.1% versus 9.6%, and constipation in 25.4% versus 9.3% (Aronne et al., N Engl J Med 2025). Adverse-event discontinuation climbed with dose across the obesity program, reaching roughly 10% at the 36 mg dose versus about 2.6% on placebo. Stepping the dose up over weeks to months is the documented strategy for keeping those effects tolerable.

Efficacy by Dose

Both weight loss and glucose control in the trials were dose-dependent — larger doses produced larger effects, which is the trade-off against the higher GI adverse-event rates above.

Weight (ATTAIN-1, obesity without required diabetes, 72 weeks): the trial reported approximately -7.8% at 6 mg, -9.3% at 12 mg, and -12.4% (about 27.3 lb) at 36 mg, versus -0.9% for placebo. At the 36 mg dose, 59.6% of participants reached at least 10% loss and 39.6% reached at least 15% (Aronne et al., N Engl J Med 2025).

Weight and A1c (ACHIEVE-1, early type 2 diabetes, 40 weeks): the trial reported weight loss of about -4.7% at 3 mg, -6.1% at 12 mg, and -7.9% (about 16.0 lb) at 36 mg versus -1.6% for placebo, with A1c reductions of roughly -1.6% at 12 mg and -1.5% at 36 mg from a baseline near 8.0% (Rosenstock et al., 2025).

Where These Numbers Come From

The label schedule and the trial doses come from the FDA approval and the pivotal Phase 3 program.

The obesity data are anchored by ATTAIN-1, a 72-week Phase 3 trial in 3,127 participants that established the 6/12/36 mg dose structure and the -12.4% top-dose weight result (Aronne et al., N Engl J Med 2025). The companion ATTAIN-2 trial studied orforglipron in obesity with type 2 diabetes and reported about -10.5% weight and a -1.8% A1c reduction at 36 mg (ATTAIN-2, Lancet 2025). Glucose-focused dosing comes from ACHIEVE-1, which used a 1 mg starting dose escalated in 4-week steps (Rosenstock et al., 2025).

The wider dose-finding range came earlier: a Phase 2 obesity trial explored 12 to 45 mg and reported up to roughly -14.7% mean weight at the top dose over 36 weeks (Phase 2 obesity, N Engl J Med 2023), and a Phase 2 type 2 diabetes trial tested 3 to 45 mg against placebo (Frias et al., Lancet 2023). The commercial 0.8 mg-to-17.2 mg tablet schedule was set at approval and is separate from these capsule doses.

How It Compares

Orforglipron is an oral GLP-1 monoagonist. The injectable incretin drugs act on more receptors: tirzepatide is a dual GLP-1/GIP agonist, and retatrutide is a triple GLP-1/GIP/glucagon agonist. These are indirect cross-trial comparisons — different populations, durations, and endpoints, not head-to-head studies — so they describe the general landscape, not a ranking.

On top-dose weight loss in obesity trials, orforglipron's ATTAIN-1 result of about -12.4% at 72 weeks sits below tirzepatide's roughly -21% at 72 weeks in SURMOUNT-1 (Jastreboff et al., N Engl J Med 2022) and retatrutide's roughly -24% at 48 weeks in Phase 2 (Jastreboff et al., N Engl J Med 2023). The differentiator the trials point to is not peak efficacy but format: orforglipron is an oral small molecule with no injection and no cold-chain requirement.

Side Effects & Safety

• Gastrointestinal effects dominate — nausea, vomiting, diarrhea, and constipation were the most common adverse events in ATTAIN-1 and rose with dose.
• Adverse-event discontinuation reached roughly 10% at the 36 mg dose across the obesity program versus about 2.6% on placebo.
• No clinically meaningful liver-enzyme signal (ALT/AST/ALP/bilirubin) was reported in Phase 1-2 data.
• No pancreatitis, retinal, or optic-neuropathy signal has been reported to date; post-approval pharmacovigilance is ongoing.
• Adverse-event rates track dose, which is the rationale for the stepwise titration described above.

Related Guides

• Orforglipron Approved: First Oral GLP-1 Pill — the FDA approval, cost, and efficacy context
• Orforglipron vs Oral Semaglutide (ACHIEVE-3) — head-to-head oral GLP-1 comparison
• Orforglipron for Weight Maintenance After Injectables — switching from injections to the pill
• Retatrutide Dosing Guide — injectable triple-agonist dosing reference
• Tirzepatide Dosing Guide — injectable dual-agonist dosing reference

References

This article is for educational and informational purposes only. It is not medical advice. Orforglipron is a prescription drug; dosing decisions are made with a licensed physician. Consult a licensed healthcare provider before starting, stopping, or changing any medication.